Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

Zhejiang Kanglaite Pharmaceutical

Status and phase: Terminated; Phase 2

Conditions: Stage IV NSCLC

Treatments: Drug: Kanglaite Injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT01640730

KLT-NSCLC-004

Details and patient eligibility

About

This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• confirmed (within last 3 months)progressive Stage IV NSCLC
• estimated life span of 3 months
• phase angle of at least 5 as measured by bioimpedance

Exclusion criteria

• currently taking a lipid lowering medications
• has an imminently life threatening condition
• has pre-existing liver disease
• known allergy to soybeans
• uncontrolled diabetes or uncontrolled disturbance of lipid metabolism
• pregnant or lactating
• has a pacemaker or other implantable electronic medical device

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

Kanglaite injection

Experimental group

Treatment:

Drug: Kanglaite Injection